High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy

Condition:   Hypercholesterolemia
Interventions:   Other: placebo;   Drug: alirocumab SAR236553 (REGN727);   Drug: pravastatin;   Drug: simvastatin;   Drug: fluvastatin;   Drug: atorvastatin;   Drug: pitavastatin;   Drug: rosuvastatin
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Not yet recruiting - verified April 2014

Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia

Conditions:   Hypercholesterolemia;   Hyperlipoproteinemia Type II
Interventions:   Drug: AEM-28;   Drug: Normal Saline
Sponsor:   LipimetiX Development, LLC
Recruiting - verified April 2014

A Multiple Dose Study Of PF-06678552 In Healthy Subjects

Condition:   Healthy
Interventions:   Drug: PF-06678552;   Drug: Placebo;   Drug: PF-06678552;   Drug: Placebo;   Drug: PF-06678552;   Drug: Placebo;   Drug: PF-06678552;   Drug: Placebo;   Drug: PF-06678552;   Drug: Placebo;   Drug: PF-06678552;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Condition:   Hypercholesterolemia
Interventions:   Drug: ETC-1002;   Drug: Placebo
Sponsors:   Esperion Therapeutics;   Medpace, Inc.
Recruiting - verified April 2014

Dose Ranging Study Of PF-04950615 In Hypercholesterolemic Japanese Subjects

Condition:   Hypercholesterolemia
Interventions:   Drug: PF-04950615;   Drug: PF-04950615;   Drug: PF-04950615;   Drug: Placebo;   Drug: Ezetimibe;   Drug: PF-04950615;   Drug: PF-04950615;   Drug: PF-04950615;   Drug: Placebo
Sponsor:   Pfizer
Not yet recruiting - verified April 2014

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553 (REGN727) Dose Regimen A;   Drug: alirocumab SAR236553 (REGN727) Dose Regimen B;   Drug: alirocumab matching placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2014

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Condition:   Hyperlipidemia
Interventions:   Drug: Part A, Atorvastatin;   Other: Part A, Placebo (administered orally);   Drug: Part B, Evolocumab;   Other: Part B, Placebo (administered orally);   Drug: Part B, Ezetimibe;   Other: Part B, Placebo (administered subcutaneously);   Drug: Part C, Evolocumab
Sponsor:   Amgen
Recruiting - verified April 2014

A 52 Week Study To Assess The Use Of RN316 (PF-04950615) In Subjects With Heterozygous Familial Hypercholesterolemia

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: PF-04950615;   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

Randomized Clinical Trial Of RN316 (PF-04950615) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: PF-04950615;   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

Actual Use Trial of Atorvastatin Calcium 10 mg

Condition:   Hypercholesterolemia
Intervention:   Drug: Atorvastatin calcium 10 mg
Sponsor:   Pfizer
Recruiting - verified April 2014

Open Label Study of Long Term Safety Evaluation of Alirocumab

Condition:   Hypercholesterolemia
Intervention:   Drug: Alirocumab SAR236553 (REGN727)
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2014

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4)

Condition:   Hypercholesterolemia
Interventions:   Drug: Anacetrapib;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

Open Label Study of Long Term Evaluation Against LDL-C Trial-2

Condition:   Hyperlipidemia and Mixed Dyslipidemia
Interventions:   Drug: evolocumab (AMG 145) and standard of care;   Other: Standard of care
Sponsor:   Amgen
Recruiting - verified April 2014

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

Condition:   Hypercholesterolemia
Interventions:   Drug: Evolocumab (AMG 145);   Other: Placebo
Sponsor:   Amgen
Recruiting - verified April 2014

Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E

Condition:   Fatty Liver
Interventions:   Dietary Supplement: Vitamin E 200 IU/d;   Dietary Supplement: Vitamin E 400 IU/d;   Dietary Supplement: Vitamin E 800 IU/d;   Behavioral: Diet and Exercise
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2014

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

Condition:   Hyperlipidemia
Interventions:   Drug: Evolocumab (AMG 145);   Other: Placebo
Sponsor:   Amgen
Completed - verified April 2014

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Device: Evolocumab (AMG 145);   Device: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Recruiting - verified April 2014

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Condition:   Hyperlipidemia
Interventions:   Drug: Evolocumab (AMG 145);   Other: Placebo (administered subcutaneously);   Drug: Ezetimibe;   Other: Placebo (administered orally)
Sponsor:   Amgen
Completed - verified April 2014

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Condition:   Hyperlipidemia
Interventions:   Drug: Evolocumab (AMG 145);   Drug: Ezetimibe;   Other: Placebo (administered subcutaneously);   Other: Placebo (administered orally)
Sponsor:   Amgen
Completed - verified April 2014

U of A/ U of M Beans and Peas Health Claim Project

Condition:   Hypercholesterolemia
Interventions:   Dietary Supplement: Beans;   Dietary Supplement: Control (rice);   Dietary Supplement: Peas
Sponsors:   University of Alberta;   Alberta Innovates Health Solutions;   Pulse Canada;   University of Manitoba
Recruiting - verified April 2014

Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis

Condition:   Multiple Sclerosis
Intervention:  
Sponsor:   Oregon Health and Science University
Recruiting - verified April 2014

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

Condition:   Homozygous Familial Hypercholesterolemia
Interventions:   Biological: Evolocumab (AMG145);   Biological: Evolocumab (AMG145);   Other: Placebo
Sponsor:   Amgen
Completed - verified April 2014

Investigation of the Effect of Dietary Nitrate Treatment on Endothelial Function and Platelet Reactivity in Hypercholesterolemics.

Condition:   Hypercholesterolemia
Intervention:   Dietary Supplement: beetroot juice
Sponsors:   Queen Mary University of London;   British Heart Foundation
Completed - verified April 2014

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Conditions:   Hypercholesterolemia;   Heterozygous Familial
Interventions:   Drug: mipomersen sodium 200 mg;   Drug: Placebo;   Drug: mipomersen sodium 70 mg
Sponsors:   Sanofi;   Genzyme, a Sanofi Company
Active, not recruiting - verified April 2014

Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease

Conditions:   Kawasaki Disease;   Aneurysm, Coronary
Intervention:   Drug: Atorvastatin
Sponsors:   National Taiwan University Hospital;   National Science Council, Taiwan
Recruiting - verified April 2014

TACTICS (Targeting Adherence to Cholesterol-lowering Therapy to Improve Control Study)

Condition:   Hypercholesterolemia
Interventions:   Behavioral: stage-matched intervention;   Behavioral: framing effects intervention;   Behavioral: attention placebo intervention
Sponsor:   Narrows Institute for Biomedical Research
Completed - verified April 2014

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Conditions:   Psoriasis;   Metabolic Syndrome;   Hyperlipidemia;   Obesity;   Hypertension
Intervention:   Drug: Etanercept
Sponsors:   Massachusetts General Hospital;   Amgen
Terminated - verified April 2014

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers

Conditions:   Atherosclerosis;   Hypercholesterolemia
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2014

Get CardioSmart

You're Invited